Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Payables: 2023-2024

Historic Payables for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $5.6 million.

  • BioLineRx's Payables fell 44.70% to $3.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.4 million, marking a year-over-year decrease of 45.69%. This contributed to the annual value of $5.6 million for FY2024, which is 48.63% down from last year.
  • BioLineRx's Payables amounted to $5.6 million in FY2024, which was down 48.63% from $10.9 million recorded in FY2023.
  • In the past 5 years, BioLineRx's Payables registered a high of $10.9 million during FY2023, and its lowest value of $5.6 million during FY2024.
  • For the 2-year period, BioLineRx's Payables averaged around $8.2 million, with its median value being $8.2 million (2023).
  • Data for BioLineRx's Payables shows a maximum YoY plummeted of 48.63% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows BioLineRx's Payables stood at $10.9 million in 2023, then tumbled by 48.63% to $5.6 million in 2024.